B CELL MALIGNANCIES
Clinical trials for B CELL MALIGNANCIES explained in plain language.
Never miss a new study
Get alerted when new B CELL MALIGNANCIES trials appear
Sign up with your email to follow new studies for B CELL MALIGNANCIES, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New antibody drug takes aim at Hard-to-Treat blood cancers
Disease control Recruiting nowThis study tests an experimental drug called AZD5492 in people with B-cell blood cancers (like lymphoma or leukemia) that have come back or not responded to at least two prior treatments. The drug works by helping the body's immune T-cells find and attack cancer cells. The main g…
Matched conditions: B CELL MALIGNANCIES
Phase: PHASE1, PHASE2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated May 26, 2026 03:55 UTC
-
New drug duo aims to wipe out hidden leukemia cells
Disease control Recruiting nowThis study tests whether adding emavusertib to a standard targeted therapy (zanubrutinib) can better control chronic lymphocytic leukemia and related B-cell cancers. About 108 adults with these cancers will receive the combination. The goal is to see if the combo can make cancer …
Matched conditions: B CELL MALIGNANCIES
Phase: PHASE2 • Sponsor: Curis, Inc. • Aim: Disease control
Last updated May 26, 2026 03:46 UTC
-
MRNA technology takes on blood cancer in early trial
Disease control Recruiting nowThis early-phase study tests a new mRNA-based drug that targets a protein called CD19 on cancer cells. It is for adults with B-cell blood cancers (like lymphoma or leukemia) who have not responded to standard treatments. The drug is delivered via lipid nanoparticles, similar to C…
Matched conditions: B CELL MALIGNANCIES
Phase: EARLY_PHASE1 • Sponsor: Xinqiao Hospital of Chongqing • Aim: Disease control
Last updated May 22, 2026 14:01 UTC
-
Supercharged immune cells take on multiple cancer targets at once
Disease control Recruiting nowThis study tests a new approach using a mix of specially engineered immune cells (CAR-T cells) that can recognize up to seven different markers on B-cell blood cancers. The goal is to see if targeting multiple proteins at once is safe and works better than single-target treatment…
Matched conditions: B CELL MALIGNANCIES
Phase: PHASE1, PHASE2 • Sponsor: Shenzhen Geno-Immune Medical Institute • Aim: Disease control
Last updated May 20, 2026 11:54 UTC
-
Engineered immune cells take on Hard-to-Treat blood cancers
Disease control Recruiting nowThis study tests a new treatment called 4SCAR19 for people with B-cell cancers that have come back or not responded to standard therapy. The treatment uses a patient's own immune cells, modified in a lab to better find and attack cancer cells. The goal is to check if it is safe a…
Matched conditions: B CELL MALIGNANCIES
Phase: PHASE1, PHASE2 • Sponsor: Shenzhen Geno-Immune Medical Institute • Aim: Disease control
Last updated May 19, 2026 11:47 UTC
-
Engineered immune cells take on tough blood cancers
Disease control Recruiting nowThis study tests a new treatment for people with certain blood cancers (B-cell malignancies) that have come back or not responded to standard therapies. The treatment uses the patient's own immune cells, which are modified in a lab to recognize and attack cancer cells carrying a …
Matched conditions: B CELL MALIGNANCIES
Phase: PHASE1, PHASE2 • Sponsor: Sheba Medical Center • Aim: Disease control
Last updated May 11, 2026 20:47 UTC